Chinese biotech Innovent Biologics, Inc., backed by Singapore’s Temasek Holdings, is seeking to raise US$400 million to US$500 million in an initial public (IPO) offering in Hong Kong. Cornerstone investors including Sequoia Capital China, Shanghai-based Greenwoods Investment, Temasek Holdings Private Limited, Hong Kong-based asset management company Value Partners and American financial services company Capital Group have […]

Temasek-Backed Biotech Firm Innovent Seeks To Raise Up To $500M In HK IPO appeared first on China Money Network.